3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Cholangiocarcinoma
5
Urinary Bladder Neoplasms
3
Acrocephalosyndactylia
3
Stomach Neoplasms
2
Glioblastoma
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Upper Tract Urothelial Carcinomas
1
Tumor With Alterations of the FGF-R
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Rectal Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Oncogenic osteomalacia
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Hypophosphatemia
1
Hematologic Neoplasms
1
Glioma
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Advanced Gastrointestinal Stromal Tumor (GIST)
1
Interventions
Cyclophosphamide
87
fludarabine
74
Tacrolimus
45
fludarabine phosphate
44
Mycophenolic Acid
42
Whole-Body Irradiation
41
Busulfan
35
Melphalan
31
Antilymphocyte Serum
24
thymoglobulin
22
Methotrexate
22
Rituximab
21
Standard of Care
20
Sirolimus
20
Azacitidine
20
venetoclax
19
Thiotepa
19
Stem Cell Transplantation
18
Granulocyte Colony-Stimulating Factor
18
Practice Guidelines as Topic
16
Cytarabine
16
Nivolumab
15
Filgrastim
15
Dexamethasone
14
Cyclosporine
13
Bortezomib
13
Mesna
12
Peripheral Blood Stem Cell Transplantation
11
trametinib
10
Specimen Handling
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Neoplasms
×
infigratinib
×
Clear all
NCT02160041
2019-06-18
CBGJ398XUS04
Novartis
Phase 2
Terminated
84 enrolled
15 charts